K190397

Substantially Equivalent

Immunalysis Carisoprodol Metabolite / Meprobamate Urine HEIA

Applicant: Immunalysis Corporation
Product code: QBK
Advisory panel: Clinical Toxicology
Date received: 2019-02-19
Decision date: 2019-11-15
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Pomona, CA, US

Download summary PDF View on FDA.gov ↗

Data sourced from openFDA. This site is unofficial and independent of the FDA.